Literature DB >> 24936593

SAGA/ADA complex subunit Ada2 is required for Cap1- but not Mrr1-mediated upregulation of the Candida albicans multidrug efflux pump MDR1.

Bernardo Ramírez-Zavala1, Selene Mogavero2, Eva Schöller1, Christoph Sasse1, P David Rogers3, Joachim Morschhäuser4.   

Abstract

Overexpression of the multidrug efflux pump MDR1 is one mechanism by which the pathogenic yeast Candida albicans develops resistance to the antifungal drug fluconazole. The constitutive upregulation of MDR1 in fluconazole-resistant, clinical C. albicans isolates is caused by gain-of-function mutations in the zinc cluster transcription factor Mrr1. It has been suggested that Mrr1 activates MDR1 transcription by recruiting Ada2, a subunit of the SAGA/ADA coactivator complex. However, MDR1 expression is also regulated by the bZIP transcription factor Cap1, which mediates the oxidative stress response in C. albicans. Here, we show that a hyperactive Mrr1 containing a gain-of-function mutation promotes MDR1 overexpression independently of Ada2. In contrast, a C-terminally truncated, hyperactive Cap1 caused MDR1 overexpression in a wild-type strain but only weakly in mutants lacking ADA2. In the presence of benomyl or H2O2, compounds that induce MDR1 expression in an Mrr1- and Cap1-dependent fashion, MDR1 was upregulated with the same efficiency in wild-type and ada2Δ cells. These results indicate that Cap1, but not Mrr1, recruits Ada2 to the MDR1 promoter to induce the expression of this multidrug efflux pump and that Ada2 is not required for MDR1 overexpression in fluconazole-resistant C. albicans strains containing gain-of-function mutations in Mrr1.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24936593      PMCID: PMC4135829          DOI: 10.1128/AAC.03065-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Authors:  D Sanglard; F Ischer; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

2.  Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates.

Authors:  S Wirsching; S Michel; J Morschhäuser
Journal:  Mol Microbiol       Date:  2000-05       Impact factor: 3.501

3.  Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance.

Authors:  G D Albertson; M Niimi; R D Cannon; H F Jenkinson
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid.

Authors:  G A Köhler; T C White; N Agabian
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

5.  Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene.

Authors:  R Ben-Yaacov; S Knoller; G A Caldwell; J M Becker; Y Koltin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  The SAT1 flipper, an optimized tool for gene disruption in Candida albicans.

Authors:  Oliver Reuss; Ashild Vik; Roberto Kolter; Joachim Morschhäuser
Journal:  Gene       Date:  2004-10-27       Impact factor: 3.688

7.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

8.  Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation.

Authors:  V Gupta; A Kohli; S Krishnamurthy; N Puri; S A Aalamgeer; S Panwar; R Prasad
Journal:  Curr Genet       Date:  1998-09       Impact factor: 3.886

9.  Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations.

Authors:  A M Gillum; E Y Tsay; D R Kirsch
Journal:  Mol Gen Genet       Date:  1984

10.  The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans.

Authors:  Christoph Sasse; Rebecca Schillig; Franziska Dierolf; Michael Weyler; Sabrina Schneider; Selene Mogavero; P David Rogers; Joachim Morschhäuser
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

View more
  12 in total

1.  Deletion of ADA2 Increases Antifungal Drug Susceptibility and Virulence in Candida glabrata.

Authors:  Shang-Jie Yu; Ya-Lin Chang; Ying-Lien Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Induction of Candida albicans drug resistance genes by hybrid zinc cluster transcription factors.

Authors:  Sabrina Schneider; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

3.  Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance.

Authors:  Zhongle Liu; Lawrence C Myers
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Authors:  Kristy Koselny; Julianne Green; Louis DiDone; Justin P Halterman; Annette W Fothergill; Nathan P Wiederhold; Thomas F Patterson; Melanie T Cushion; Chad Rappelye; Melanie Wellington; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 5.  Oxidative stress response pathways in fungi.

Authors:  Hajar Yaakoub; Sara Mina; Alphonse Calenda; Jean-Philippe Bouchara; Nicolas Papon
Journal:  Cell Mol Life Sci       Date:  2022-06-01       Impact factor: 9.261

6.  Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.

Authors:  Amy R Biermann; Deborah A Hogan
Journal:  mSphere       Date:  2022-04-27       Impact factor: 5.029

7.  The SAGA and NuA4 component Tra1 regulates Candida albicans drug resistance and pathogenesis.

Authors:  Iqra Razzaq; Matthew D Berg; Yuwei Jiang; Julie Genereaux; Deeva Uthayakumar; Grace H Kim; Michelle Agyare-Tabbi; Viola Halder; Christopher J Brandl; Patrick Lajoie; Rebecca S Shapiro
Journal:  Genetics       Date:  2021-10-02       Impact factor: 4.402

Review 8.  Oxidative stress responses in the human fungal pathogen, Candida albicans.

Authors:  Alessandra da Silva Dantas; Alison Day; Mélanie Ikeh; Iaroslava Kos; Beatrice Achan; Janet Quinn
Journal:  Biomolecules       Date:  2015-02-25

9.  Tanshinone IIA Protects Endothelial Cells from H₂O₂-Induced Injuries via PXR Activation.

Authors:  Haiyan Zhu; Zhiwu Chen; Zengchun Ma; Hongling Tan; Chengrong Xiao; Xianglin Tang; Boli Zhang; Yuguang Wang; Yue Gao
Journal:  Biomol Ther (Seoul)       Date:  2017-11-01       Impact factor: 4.634

10.  Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications.

Authors:  Wenli Feng; Jing Yang; Lu Yang; Qing Li; Xin Zhu; Zhiqin Xi; Zusha Qiao; Wen Cen
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.